ArticleCell reports2016
Diversity of the CD4 T Cell Alloresponse: The Short and the Long of It.
Article in Cell reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 43 citations in OpenAlex.
- Implications of MHC-restricted immunopeptidome in transplantation.Frontiers in immunology · 2024Review
- Allorecognition Unveiled: Integrating Recent Breakthroughs Into the Current Paradigm.Transplant international : official journal of the European Society for Organ Transplantation · 2024Review
- Heterogeneity in allospecific T cell function in transplant-tolerant hosts determines susceptibility to rejection following infection.The Journal of clinical investigation · 2023Article
- TCR Sequencing in Mouse Models of Allorecognition Unveils the Features of Directly and Indirectly Activated Clonotypes.International journal of molecular sciences · 2023Article
- Cellular activation pathways and interaction networks in vascularized composite allotransplantation.Frontiers in immunology · 2023Review
- Clinical application of immune repertoire sequencing in solid organ transplant.Frontiers in immunology · 2023Review
- Reduced Satb1 expression predisposes CD4Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Activation and regulation of alloreactive T cell immunity in solid organ transplantation.Nature reviews. Nephrology · 2022Review
- Detection of alloreactive T cells from cryopreserved human peripheral blood mononuclear cells.Journal of immunological methods · 2021Article
- Recent advances in our understanding of the allograft response.Faculty reviews · 2021Review
- The suppressive effect on CD4 T cell alloresponse against endothelial HLA-DR via PD-L1 induced by anti-A/B ligation.Clinical and experimental immunology · 2020Article
- Ex-vivo delivery of monoclonal antibody (Rituximab) to treat human donor lungs prior to transplantation.EBioMedicine · 2020Article
- Evidence for the alloimmune basis and prognostic significance of Borderline T cell-mediated rejection.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2020Article
- Transplantation tolerance modifies donor-specific B cell fate to suppress de novo alloreactive B cells.The Journal of clinical investigation · 2020Article
- Resilience of T cell-intrinsic dysfunction in transplantation tolerance.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Review
- Prolongation of allograft survival by passenger donor regulatory T cells.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2019Article
- Data regarding transplant induced germinal center humoral autoimmunity.Data in brief · 2019Article
- Mechanisms of Immune Tolerance in Liver Transplantation-Crosstalk Between Alloreactive T Cells and Liver Cells With Therapeutic Prospects.Frontiers in immunology · 2019Review
- Autoantibody production significantly decreased with APRIL/BLyS blockade in murine chronic rejection kidney transplant model.PloS one · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
Abstract
MHC alloantigen is recognized by two pathways: "directly," intact on donor cells, or "indirectly," as self-restricted allopeptide. The duration of each pathway, and its relative contribution to allograft vasculopathy, remain unclear. Using a murine model of chronic allograft rejection, we report that direct-pathway CD4 T cell alloresponses, as well as indirect-pathway responses against MHC class II alloantigen, are curtailed by rapid elimination of donor hematopoietic antigen-presenting cells. In contrast, persistent presentation of epitope resulted in continual division and less-profound contraction of the class I allopeptide-specific CD4 T cell population, with approximately 10,000-fold more cells persisting than following acute allograft rejection. This expanded population nevertheless displayed sub-optimal anamnestic responses and was unable to provide co-stimulation-independent help for generating alloantibody. Indirect-pathway CD4 T cell responses are heterogeneous. Appreciation that responses against particular alloantigens dominate at late time points will likely inform development of strategies aimed at improving transplant outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.